Cardiovascular risk in chronic kidney disease - what is new in the pathogenesis and treatment?

Cardiovascular risk in chronic kidney disease - what is new in the pathogenesis and treatment?
Postgrad Med. 2018 May 30;:
Authors: Bazyluk A, Malyszko J, Zbroch E
Abstract
The prevalence of chronic kidney disease has increased markedly over past decades due to the aging of the worldwide population. Despite the progress in the prevention and treatment, the cardiovascular morbidity and mortality remains high among patients with chronic kidney disease. Although chronic kidney disease is a progressive and irreversible condition, it is possible to slow decreasing kidney function, as well as the development and progression of associated with kidney disease comorbidities. Diabetes mellitus (DM) has become major cause of chronic kidney disease worldwide. It is estimated that the prevalence of diabetes will increase from 425 million worldwide in 2017 to 629 million by 2045, substantially the percentage of diabetic nephropathy among CKD patients is set to rise markedly. The results of multicentre trials concerning novel antidiabetic drugs suggest that efficacy in reducing cardiovascular risk is independent of the improvement in glycemic control. This review discusses underlying causes of high cardiovascular risk and strategies reducing individual burden among chronic kidney disease patients.
PMID: 29846140 [PubMed - as supplied by publisher]

Source: Postgraduate Medicine - June 1, 2018 Category: Internal Medicine Tags: Postgrad Med Source Type: research